Why constipation happens on Mounjaro — and what you can do about it

What the trial data recorded about constipation rates

The SURMOUNT-1 study (the pivotal phase 3 trial of tirzepatide for weight management, published in the New England Journal of Medicine) tracked gastrointestinal side effects systematically across thousands of participants. Constipation was among the adverse events reported at a notably higher rate in the tirzepatide groups than in the placebo group, alongside nausea and diarrhoea. The pattern was consistent across dose levels, though the frequency and severity tended to be higher at greater doses. The NHS medicines page for tirzepatide lists constipation as a common side effect (meaning it affects roughly one in ten people or more) and describes it alongside the broader cluster of gut-related effects that tirzepatide produces.

This is worth sitting with for a moment. Constipation is not a sign that something has gone wrong with your treatment, and it is not your body rejecting the medicine. It is the digestive system responding to a drug that is, by design, changing how quickly it processes food. Understanding that distinction tends to reduce anxiety considerably, and if you are asking whether you can get constipated on Mounjaro, the short answer is yes, it is a recognised and well-documented response. If you want more context on the full side-effect profile, the Mounjaro side effects overview covers the wider picture.

Why Mounjaro specifically slows the bowel

Tirzepatide activates two receptors (GIP and GLP-1) both of which influence gut motility. The GLP-1 pathway in particular is well established as a brake on gastric emptying: food moves more slowly from the stomach into the small intestine, which is a large part of why the medicine reduces appetite so effectively. The colon does not escape this effect. Slower transit means the colon has more time to absorb water from stool, and drier, harder stool is harder to pass.

There is also a secondary effect worth mentioning: people on Mounjaro typically eat and drink less than before, especially in the early weeks. Reduced fluid and fibre intake compound the motility slowdown. One quick check worth doing each morning is to glance at the colour of your first urine of the day, pale straw or clear suggests adequate hydration, dark amber is a prompt to drink more water before anything else. It takes under a minute and gives you a reliable daily signal. If you are wondering in more detail about whether Mounjaro makes you constipated and what drives it, the dedicated page goes into the mechanisms at length. The detailed guide to managing constipation on Mounjaro covers practical strategies in full.

Practical steps that can genuinely help

Before reaching for any product, the basics are worth prioritising, and they tend to be more effective than people expect. Adequate water intake across the day (most adults need around 1.5–2 litres, more in warm weather or with physical activity) is the single most consistent recommendation. Soluble fibre (oats, lentils, ground flaxseed, soft-cooked vegetables) adds bulk without the irritation that some high-fibre supplements cause in a gut that is already sensitive to change. Gentle, regular movement after meals can encourage peristalsis.

If constipation persists beyond a week or two despite these measures, a pharmacist or your prescriber can advise on suitable short-term laxatives. Osmotic laxatives such as macrogol are often suggested first. What matters here is that you do not self-manage indefinitely without a clinical conversation, a prescriber can review whether your current dose or titration pace is contributing, and whether any adjustment is appropriate. You can contact the nume aftercare team seven days a week if questions come up between reviews. More on adjusting expectations by dose is available on the Mounjaro treatment overview.

When constipation is a signal to get medical help urgently

Most constipation on tirzepatide is uncomfortable but manageable. There are signs, though, that should prompt you to call NHS 111 or go to A&E rather than wait. Severe abdominal pain that does not ease (particularly if it spreads towards the back, or is accompanied by vomiting you cannot control) needs assessment the same day. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; its hallmark is exactly that pattern of severe, persistent stomach pain, sometimes radiating to the back. Do not assume it is constipation and manage it at home.

Other signs that warrant prompt contact with a healthcare professional include no bowel movement for more than five to seven days despite taking a laxative, blood in the stool, unexplained fever alongside abdominal pain, or signs of dehydration such as very dark urine, dizziness or rapid heartbeat. If you are constipated on Mounjaro and unsure whether your symptoms fall into the manageable category or need more urgent attention, that page can help you decide. Patients and carers can report suspected side effects (including those not listed in the Patient Information Leaflet) directly to the MHRA via the Yellow Card scheme. That feedback genuinely shapes how the regulator monitors medicines post-authorisation. If you have broader questions about suitability or side effect management, our prescribers discuss all of this at the free consultation, constipation included.